Browse

Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling

DC Field Value Language
dc.contributor.authorShin, Nari-
dc.contributor.authorJung, Namhee-
dc.contributor.authorLee, Seung-Eun-
dc.contributor.authorKong, Dasom-
dc.contributor.authorKim, Nam G.-
dc.contributor.authorKook, Myung G.-
dc.contributor.authorPark, Hwanhee-
dc.contributor.authorChoi, Soon W.-
dc.contributor.authorLee, Seunghee-
dc.contributor.authorKang, Kyung-Sun-
dc.date.accessioned2021-09-02T05:22:13Z-
dc.date.available2021-09-02T14:23:25Z-
dc.date.issued2021-08-28-
dc.identifier.citationStem Cell Research & Therapy. 2021 Aug 28;12(1):482-
dc.identifier.urihttps://doi.org/10.1186/s13287-021-02547-8-
dc.identifier.urihttps://hdl.handle.net/10371/174861-
dc.description.abstractAbstract

Background
Human mesenchymal stem cells (hMSCs) therapy has recently been considered a promising treatment for atopic dermatitis (AD) due to their immunomodulation and tissue regeneration ability. In our previous studies, we demonstrated that hMSCs alleviate allergic inflammation in murine AD model by inhibiting the activation of mast cells and B cells. Also our phase I/IIa clinical trial showed clinical efficacy and safety of hMSCs in moderate-to-severe adult AD patients. However, hMSCs therapy against atopic dermatitis have had poor results in clinical field. Therefore, we investigated the reason behind this result. We hypothesized that drug–cell interaction could interfere with the therapeutic efficacy of stem cells, and investigated whether coadministration with pimecrolimus, one of the topical calcineurin inhibitors, could influence the therapeutic potential of human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) in AD.


Methods
hUCB-MSCs were subcutaneously injected to AD-induced mice with or without pimecrolimus topical application. To examine whether pimecrolimus influenced the immunomodulatory activity of hUCB-MSCs, hUCB-MSCs were treated with pimecrolimus.


Results
Pimecrolimus disturbed the therapeutic effect of hUCB-MSCs when they were co-administered in murine AD model. Moreover, the inhibitory functions of hUCB-MSCs against type 2 helper T (Th2) cell differentiation and mast cell activation were also deteriorated by pimecrolimus treatment. Interestingly, we found that pimecrolimus decreased the production of PGE2, one of the most critical immunomodulatory factors in hUCB-MSCs. And we demonstrated that pimecrolimus downregulated COX2-PGE2 axis by inhibiting nuclear translocation of NFAT3.


Conclusions
Coadministration of pimecrolimus with hMSCs could interfere with the therapeutic efficacy of hMSCs in atopic dermatitis, and this is the first study that figured out the interaction of hMSCs with other drugs in cell therapy of atopic dermatitis. Therefore, this study might give rise to improvement of the clinical application of hMSCs therapy and facilitate the widespread application of hMSCs in clinical field.
-
dc.titlePimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling-
dc.typeJournal Article-
dc.language.rfc3066en-
dc.rights.holderThe Author(s)-
dc.date.updated2021-08-29T03:13:00Z-
Appears in Collections:
Seoul National University(서울대학교)Seoul National University Bulletin(서울대학교 요람) Seoul National University Bulletin, 1965-1966 (서울대학교 요람)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse